Sugi Predict

Sugi Predict / Compounds / SCHEMBL93948

SCHEMBL93948

SCHEMBL93948

O=C(O)CCC(=O)NCc1ccccc1

nearest known ligand 0.89

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.75
▸ MEN1 O00255 2/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ ALDH1A1 P00352 3/20 0.71
▸ HTT P42858 2/20 0.71
▸ L3MBTL1 Q9Y468 2/20 0.67
▸ CYP3A4 P08684 1/20 0.67
▸ CYP2C19 P33261 1/20 0.67
▸ TSHR P16473 3/20 0.62
▸ HPGD P15428 2/20 0.62
▸ EPHX2 P34913 1/20 0.62
▸ RECQL P46063 1/20 0.62
▸ POLB P06746 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27909131 0.89 MEN1 (0.86) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL9208372 0.89 GAA (0.89) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL14254953 0.87 MEN1 (0.89) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL27909119 0.87 MEN1 (0.89) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL2942358 0.86 MEN1 (0.96) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL9680630 0.85 KMT2A (0.59) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL6307396 0.85 GAA (0.70) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL4900724 0.85 GAA (0.70) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL5607428 0.85 GAA (0.70) GAAMEN1KMT2AALDH1A1HTT
SCHEMBL9517546 0.85 GAA (0.70) GAAMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492225-B2 Melanocyte-regulating peptides IDP DISCOVERY PHARMA, S.L. (ES) 2025-12-09 — — US disclosed
CN-119451974-A Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens 巴塞罗那全球健康研究所私人基金会 2025-02-14 — — CN disclosed
US-20240294573-A1 CONSTRAINED PEPTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-09-05 — — US disclosed
US-20240083943-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2024-03-14 — — US disclosed
CN-116964074-A Peptides that modulate VEGF IDP研发制药有限公司 2023-10-27 — — CN disclosed
CN-111263768-B anticancer peptides IDP研发制药有限公司 2023-10-13 — — CN disclosed
EP-3159352-B1 STITCHED POLYPEPTIDES HARVARD COLLEGE (US) 2023-08-02 — — EP disclosed
CN-109071622-B Peptides with anticancer activity IDP研发制药有限公司（ES） 2023-01-13 — — CN disclosed
US-20220306708-A1 BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-09-29 — — US disclosed
US-11440939-B2 Anticancer peptides IDP DISCOVERY PHARMA, S.L. (ES) 2022-09-13 — — US disclosed
US-7332631-B2 These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases TRILLIUM THERAPEUTICS INC. (CA) 2008-02-19 — — US disclosed
US-7332631-B2 These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases TRILLIUM THERAPEUTICS INC. (CA) 2008-02-19 — — US disclosed
US-5907068-A TRIFLUOROMETHYLSUBSTITUTED COMPOUND INCLUDED IN PEPTIDES ZENECA INC. (US) 1999-05-25 — — US disclosed
US-5726158-A INHIBITORS OF HUMAN LEUKOCYTE ELASTASE USEFUL IN TREATING TISSUE DEGENERATIVE DISEASES; TRIFLUOROMETHYL KETONE SUBSTITUTED DI-, TRI-, AND TETRA-PEPTIDE DERIVATIVES ZENECA INC. (US) 1998-03-10 — — US disclosed
US-5414132-A Peptide intermediates ZENECA INC. (US) 1995-05-09 — — US disclosed
US-5194588-A Inhibitors of human leukocyte elastase, di-, tri- and tetra-peptides ICI AMERICAS INC. (US) 1993-03-16 — — US disclosed
EP-0189305-B1 PEPTIDE DERIVATIVES ICI AMERICAS INC. (US) 1992-07-29 — — EP disclosed
US-5055450-A Di-, tri- and tetrapeptides as inhibitors of human leukocyte elastase ICI AMERICAS INC. (US) 1991-10-08 — — US disclosed
US-4910190-A Containing a nitrogen containing heterocycle ring structure ICI AMERICAS INC. (US) 1990-03-20 — — US disclosed
EP-0189305-A2 Peptide derivatives ICI AMERICAS INC. (US) 1986-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492225-B2 Melanocyte-regulating peptides MC1R, MITF, MCHR1 GAA 3391/4885MEN1 292/4885KMT2A 995/4885
US-11440939-B2 Anticancer peptides NGLY1, SLC1A5, SSTR5 GAA 4697/4885MEN1 64/4885KMT2A 2923/4885
US-20240294573-A1 CONSTRAINED PEPTIDES IAPP, NGLY1, VIP GAA 2628/4885MEN1 253/4885KMT2A 4628/4885
US-20220306708-A1 BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF TIMCC, CCL2, SGTA GAA 3149/4885MEN1 567/4885KMT2A 4278/4885
US-20240083943-A1 VEGF-REGULATING PEPTIDES VEGFA, FLT4, FLT1 GAA 4691/4885MEN1 1193/4885KMT2A 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.